Literature DB >> 2924330

Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells.

M J Mattes1, K O Lloyd, J L Lewis.   

Abstract

Binding parameters were determined for four mouse monoclonal antibodies reacting with three antigens on the surface of fresh human ovarian carcinoma ascites cells, under nearly physiological conditions. The object of these experiments was to aid in the selection of the optimal monoclonal antibodies for intraperitoneal immunotherapy. The number of antigenic sites per cell, the effective equilibrium association constant (affinity) and the half-life for dissociation were: for Ab MH99, 1.2 x 10(6) sites/cell, (1.9-4.1) x 10(8) M-1, and 4 h; for Ab MX35, (3.2-4.1) x 10(5) sites/cell, (3.4-4.8) x 10(8) M-1, and greater than 10 h; and for Ab MW207, 1.3 x 10(5) sites/cell, (3.6-4.1) x 10(9) M-1, and 3.1 h, respectively. One of the antigens, MH99, is recognized by five different monoclonal antibodies, and competitive inhibition experiments demonstrated that two distinct determinants are present; this antigen is also recognized by the previously described Ab 17-1A. These binding data will aid the rational design of immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924330     DOI: 10.1007/BF00204989

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  CO 17-1A and related monoclonal antibodies: their production and characterization.

Authors:  M Herlyn; Z Steplewski; D Herlyn; H Koprowski
Journal:  Hybridoma       Date:  1986-07

3.  The kinetics of antibody binding to membrane antigens in solution and at the cell surface.

Authors:  D W Mason; A F Williams
Journal:  Biochem J       Date:  1980-04-01       Impact factor: 3.857

4.  Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants.

Authors:  P Giacomini; P Natali; S Ferrone
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

5.  Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells.

Authors:  M J Mattes; K Look; K Furukawa; V K Pierce; L J Old; J L Lewis; K O Lloyd
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

7.  The characteristics of binding of human recombinant interferon-gamma to its receptor on human monocytes and human monocyte-like cell lines.

Authors:  D S Finbloom; D L Hoover; L M Wahl
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.

Authors:  T C Hamilton; R C Young; K G Louie; B C Behrens; W M McKoy; K R Grotzinger; R F Ozols
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

9.  Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells.

Authors:  D Herlyn; J Powe; A H Ross; M Herlyn; H Koprowski
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

10.  Monoclonal antibodies to three widely distributed human cell surface antigens.

Authors:  M J Mattes; J G Cairncross; L J Old; K O Lloyd
Journal:  Hybridoma       Date:  1983
View more
  3 in total

1.  Molecular identification of a human carcinoma-associated glycoprotein antigen recognized by mouse monoclonal antibody FU-MK-1.

Authors:  Y Tomita; F Arakawa; T Yamamoto; M Kuwahara; R Watanabe; H Iwasaki; M Kikuchi; M Kuroki
Journal:  Jpn J Cancer Res       Date:  2000-02

2.  Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.

Authors:  Mariana Lopes dos Santos; Fernanda Perez Yeda; Lilian Rumi Tsuruta; Bruno Brasil Horta; Alécio A Pimenta; Theri Leica Degaki; Ibere C Soares; Maria Carolina Tuma; Oswaldo Keith Okamoto; Venancio A F Alves; Lloyd J Old; Gerd Ritter; Ana Maria Moro
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

3.  Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.

Authors:  Anna Gustafsson-Lutz; Tom Bäck; Emma Aneheim; Ragnar Hultborn; Stig Palm; Lars Jacobsson; Alfred Morgenstern; Frank Bruchertseifer; Per Albertsson; Sture Lindegren
Journal:  EJNMMI Res       Date:  2017-04-24       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.